Skip to main content

Table 2 Effect of surgical site infection

From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery

All OLG group (n = 223) Control group (n = 58) P value
Surgical site infection 6 (2.7%) 6 (10.3%) 0.02
 Superficial incisional 5 (2.2%) 5 (8.6%) 0.0345
 Deep incisional 1 (0.5%) 1 (1.7%) 0.371
Open OLG group (n = 91) Control group (n = 42)  
Surgical site infection 2 (2.2%) 4 (9.5%) 0.0789
 Superficial incisional 2 (2.2%) 4 (9.5%) 0.0789
 Deep incisional 0 (0%) 0 (0%)  
Laparoscopy OLG group (n = 132) Control group (n = 16)  
Surgical site infection 4 (3.0%) 2 (12.5%) 0.127
 Superficial incisional 3 (2.3%) 1 (6.3%) 0.37
 Deep incisional 1 (0.8%) 1 (6.3%) 0.205
Stomach OLG group (n = 66) Control group (n = 17)  
Surgical site infection 0 (0%) 1 (5.9%) 0.205
 Superficial incisional 0 (0%) 1 (5.9%) 0.205
 Deep incisional 0 (0%) 0 (0%)  
Colon OLG group (n = 157) Control group (n = 41)  
Surgical site infection 6 (3.8%) 5 (12.2%) 0.0523
 Superficial incisional 5 (3.2%) 4 (9.8%) 0.0904
 Deep incisional 1 (0.6%) 1 (2.4%) 0.372
  1. Control group: PVP-I group